deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00685698

Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections

An Open-Label, Single-Arm, Multi-Center Study of TG-873870 for Treating Patients With Diabetic Foot Infections of Mild to Moderate Severity Associated With Gram-Positive Pathogens

Sponsor: TaiGen Biotechnology Co., Ltd.

Updated 9 times since 2017 Last updated: Jun 13, 2025 Started: Jun 30, 2008 Primary completion: Apr 30, 2009 Completion: Jun 30, 2009
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Diabetic Foot Infections and is currently completed. TaiGen Biotechnology Co., Ltd. leads this study, which shows 9 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Aug 2025 · 11 months · monthly snapshotCompleted~Aug 2025 – ~Sep 2025 · 31 days · monthly snapshotCompleted~Sep 2025 – ~Dec 2025 · 3 months · monthly snapshotCompleted~Dec 2025 – present · 9 months · monthly snapshotCompleted

Change History

9 versions recorded
  1. Dec 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Dec 2025 [monthly]

    Completed PHASE2

  3. Aug 2025 — Sep 2025 [monthly]

    Completed PHASE2

  4. Sep 2024 — Aug 2025 [monthly]

    Completed PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

Show 4 earlier versions
  1. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  3. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jun 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • TaiGen Biotechnology Co., Ltd.
Data source: TaiGen Biotechnology Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .